Drug Delivery System for Superficial Mycoses

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$365,363.00
Award Year:
2001
Program:
STTR
Phase:
Phase II
Contract:
PHS2001-2
Award Id:
55769
Agency Tracking Number:
2R42AI041777-02
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
500 SANDAU, STE 200, SAN ANTONIO, TX 78216, SAN ANTONIO, TX, 78216
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
H RAWLS
(210) 308-0636
BDC@BIODEVCORP.COM
Business Contact:
SIEGEL, GREGG
(210) 308-0636
GSIEGEL@BIODEVCORP.COM
Research Institution:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER

UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
SAN ANTONIO, TX, 77157

Nonprofit college or university
Abstract
DESCRIPTION (Provided by the applicant): The goal of this project is to establish the safety and efficacy of a unique drug delivery system for use as a sustained-release, antifungal skin preparation for the treatment of superficial mycoses. The lifetime risk of acquiring a superficial mycotic infection is estimated to be between 10 and 20 percent. In the U.S., annual treatment costs for superficial mycoses exceed $400 million. Immunocompromised and elderly patients are particularly at risk for opportunistic dermatophyte infection, although superficial mycoses often affect people who are otherwise healthy. With an aging population, the increased use of aggressive immunosuppressive therapies, an increase in organ transplants, and the continued prevalence of the AIDS pandemic, the number of patients affected by superficial fungal infection is expected to rise. Phase I studies demonstrated the feasibility of using novel coating compositions for the treatment of superficial mycoses. The Phase II project is designed to further establish the safety and efficacy of the technology. The Specific Aims are to determine the final coating composition based on optimization and evaluation of antifungal delivery, to demonstrate safety of coatings in human studies according to FDA guidelines, and to illustrate the efficacy of coatings in a skin-stripping model in humans. PROPOSED COMMERCIAL APPLICATION: Not Available

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government